Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort StudyVince Biemans, Frank Hoentjen, Alexander Bodelier et al.|Journal of Crohn s and Colitis|2019Cited by 183
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatmentVince Biemans, C. Janneke van der Woude, Gerard Dijkstra et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 129
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registryVince Biemans, Jasmijn A M Sleutjes, Annemarie C. de Vries et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 87
Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of lifeShannon L. Kanis, C. Janneke van der Woude, Sanne Modderman et al.|Gut|2020Cited by 81
Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort StudyLauranne Derikx, Frank Hoentjen, Marten A. Lantinga et al.|Journal of Crohn s and Colitis|2020Cited by 71